Drug · CHEMBL177
AMIKACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AMIKACIN. Drugs and targets, record CHEMBL177. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL177
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 20 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases20
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| cystic fibrosis | Phase 3 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0009061 |
| pneumonia | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005249 |
| ventilator-associated pneumonia | Phase 3 | ClinicalTrials.gov | 7 | 7 | https://conductscience.org/library/drugs?q=EFO_1001865 |
| multidrug-resistant tuberculosis | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0005861 |
| Pseudomonas aeruginosa infectious disease | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0040732 |
| infection | Phase 1/2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0000544 |
| pulmonary non-tuberculous mycobacterial infection | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0018469 |
| bronchiectasis | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | https://conductscience.org/library/drugs?q=MONDO_0004822 |
| tuberculosis | Phase 1 | ClinicalTrials.gov | 2 | 1 | https://conductscience.org/library/drugs?q=MONDO_0018076 |
| Fever | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0001945 |
1 to 10 of 20Source Open Targets
See all 20 diseasesTrials78
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01799993 | Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia | Phase 3 | 725 | 2018-06-26 | amikacin | Its name | ClinicalTrials.gov |
| NCT01659866 | Antibiotic Prophylaxis for Transrectal Prostate Biopsy | Phase 4 | 563 | 2019-06-25 | amikacin | Its name | ClinicalTrials.gov |
| NCT02344004 | Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone | Phase 3 | 336 | 2018-11-20 | amikacin | Its name | ClinicalTrials.gov |
| NCT01315678 | Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections | Phase 3 | 302 | 2019-06-24 | amikacin | Its name | ClinicalTrials.gov |
| NCT01316276 | Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection | Phase 3 | 206 | 2019-07-26 | amikacin | Its name | ClinicalTrials.gov |
| NCT02081963 | Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis | Phase 4 | 178 | 2019-04-16 | amikacin | Its name | ClinicalTrials.gov |
| NCT02628600 | Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212 | Phase 3 | 163 | 2019-11-19 | amikacin | Its name | ClinicalTrials.gov |
| NCT01969799 | Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia | Phase 2 | 143 | 2017-07-02 | amikacin | Its name | ClinicalTrials.gov |
| NCT04677543 | Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex | Phase 3 | 99 | 2024-06-28 | alis | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT01315236 | Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria | Phase 2 | 90 | 2019-08-21 | amikacin | Its name | ClinicalTrials.gov |
1 to 10 of 78
See all 78 trialsComparisons in its trials29
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants Who Received at Least One Dose of Study Drug and Reported an Adverse Event | 295 of 353 | 303 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Organ Failure | 69 of 353 | 67 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants Who Received at Least One Dose of Study Drug and Reported a Serious Adverse Event | 101 of 353 | 97 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale 400mg q12h vs Placebo: deaths from any cause | 86 of 353 | 85 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale 400mg q12h vs Placebo: serious adverse events | 101 of 353 | 97 of 359 | 712 | NCT01799993 | Trial comparisons |
| Cipro-susceptible vs Cipro-resistant: Number of Participants With Post-biopsy Infection. | 6 of 430 | 3 of 80 | 510 | NCT01659866 | Trial comparisons |
| Cipro-susceptible vs Cipro-resistant: deaths from any cause | 0 of 430 | 0 of 80 | 510 | NCT01659866 | Trial comparisons |
| Cipro-susceptible vs Cipro-resistant: serious adverse events | 0 of 430 | 0 of 80 | 510 | NCT01659866 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Microbiological Response at TOC Visit | 150 of 255 | 118 of 253 | 508 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Emergence of New Respiratory Pathogens During the Aerosol Treatment Period | 21 of 255 | 34 of 253 | 508 | NCT01799993 | Trial comparisons |
1 to 10 of 29
See all 29 comparisons in its trialsPapers from its trials71
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL177
GET https://conductscience.org/api/drugs/v1/CHEMBL177/trials?page=2